异麦芽糖铁阿魏木糖醇与蔗糖铁治疗缺铁性贫血的比较:随机对照试验的荟萃分析

IF 0.8 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

African Health Sciences Pub Date : 2023-10-11 DOI:10.4314/ahs.v23i3.25

Lunbo Shi, Yan Zhao, Aihua Rao

{"title":"异麦芽糖铁阿魏木糖醇与蔗糖铁治疗缺铁性贫血的比较:随机对照试验的荟萃分析","authors":"Lunbo Shi, Yan Zhao, Aihua Rao","doi":"10.4314/ahs.v23i3.25","DOIUrl":null,"url":null,"abstract":"Introduction: The efficacy of iron isomaltoside ferumoxytol versus iron sucrose to treat iron deficiency anemia remains controversial. We conduct this meta-analysis to explore the influence of iron isomaltoside ferumoxytol versus iron sucrose on iron deficiency anemia. Methods: We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through March 2021 for randomized controlled trials (RCTs) assessing the effect of iron isomaltoside ferumoxytol versus iron sucrose on iron deficiency anemia. Meta-analysis was performed using the random-effect model. Results: Four RCTs involving 3892 patients were included in the meta-analysis. Overall, compared with iron sucrose for iron deficiency anemia, iron isomaltoside showed similar change of Hb (SMD=0.14; 95% CI=-0.07 to 0.35; P=0.18), Hb responder (SMD=1.41; 95% CI=0.71 to 2.81; P=0.33), serum ferritin (SMD=15.13; 95% CI=-23.45 to 53.71; P=0.44), and transferrin saturation (SMD=1.20; 95% CI=-1.08 to 3.47; P=0.30). However, iron isomaltoside further improved serum-ferritin at week 2 than iron sucrose (SMD=204.79; 95% CI=38.23 to 371.35; P=0.02). Conclusions: Iron isomaltoside ferumoxytol showed comparable efficacy to iron sucrose for the treatment of iron deficiency anemia. Keywords: Iron isomaltoside ferumoxytol; iron sucrose; iron deficiency anemia; randomized controlled trials.","PeriodicalId":7853,"journal":{"name":"African Health Sciences","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of iron isomaltoside ferumoxytol with iron sucrose for iron deficiency anemia: a meta-analysis of randomized controlled trials\",\"authors\":\"Lunbo Shi, Yan Zhao, Aihua Rao\",\"doi\":\"10.4314/ahs.v23i3.25\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: The efficacy of iron isomaltoside ferumoxytol versus iron sucrose to treat iron deficiency anemia remains controversial. We conduct this meta-analysis to explore the influence of iron isomaltoside ferumoxytol versus iron sucrose on iron deficiency anemia. Methods: We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through March 2021 for randomized controlled trials (RCTs) assessing the effect of iron isomaltoside ferumoxytol versus iron sucrose on iron deficiency anemia. Meta-analysis was performed using the random-effect model. Results: Four RCTs involving 3892 patients were included in the meta-analysis. Overall, compared with iron sucrose for iron deficiency anemia, iron isomaltoside showed similar change of Hb (SMD=0.14; 95% CI=-0.07 to 0.35; P=0.18), Hb responder (SMD=1.41; 95% CI=0.71 to 2.81; P=0.33), serum ferritin (SMD=15.13; 95% CI=-23.45 to 53.71; P=0.44), and transferrin saturation (SMD=1.20; 95% CI=-1.08 to 3.47; P=0.30). However, iron isomaltoside further improved serum-ferritin at week 2 than iron sucrose (SMD=204.79; 95% CI=38.23 to 371.35; P=0.02). Conclusions: Iron isomaltoside ferumoxytol showed comparable efficacy to iron sucrose for the treatment of iron deficiency anemia. Keywords: Iron isomaltoside ferumoxytol; iron sucrose; iron deficiency anemia; randomized controlled trials.\",\"PeriodicalId\":7853,\"journal\":{\"name\":\"African Health Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2023-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"African Health Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4314/ahs.v23i3.25\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"African Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4314/ahs.v23i3.25","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

简介:异麦芽糖铁阿魏木糖醇与蔗糖铁治疗缺铁性贫血的疗效仍有争议。我们进行这项荟萃分析，探讨异麦芽糖铁阿魏木糖醇与蔗糖铁对缺铁性贫血的影响。方法:我们检索了PubMed、EMbase、Web of science、EBSCO和Cochrane图书馆数据库，检索了截至2021年3月的随机对照试验(rct)，以评估异麦糖苷阿魏木糖醇与蔗糖铁对缺铁性贫血的影响。采用随机效应模型进行meta分析。结果:meta分析纳入4项随机对照试验，共3892例患者。总体而言，与铁蔗糖治疗缺铁性贫血相比，铁异麦芽糖甙的Hb变化相似(SMD=0.14;95% CI=-0.07 ~ 0.35;P=0.18)， Hb反应(SMD=1.41;95% CI=0.71 ~ 2.81;P=0.33)，血清铁蛋白(SMD=15.13;95% CI=-23.45 ~ 53.71;P=0.44)，转铁蛋白饱和度(SMD=1.20;95% CI=-1.08 ~ 3.47;P = 0.30)。然而，与蔗糖铁相比，异麦芽糖铁在第2周进一步改善了血清铁蛋白(SMD=204.79;95% CI=38.23 ~ 371.35;P = 0.02)强生# x0D;结论:异麦芽糖铁阿魏木糖醇治疗缺铁性贫血的疗效与蔗糖铁相当。关键词:异麦芽糖铁;阿魏木醇;蔗糖铁;缺铁性贫血;随机对照试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Comparison of iron isomaltoside ferumoxytol with iron sucrose for iron deficiency anemia: a meta-analysis of randomized controlled trials

Introduction: The efficacy of iron isomaltoside ferumoxytol versus iron sucrose to treat iron deficiency anemia remains controversial. We conduct this meta-analysis to explore the influence of iron isomaltoside ferumoxytol versus iron sucrose on iron deficiency anemia. Methods: We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through March 2021 for randomized controlled trials (RCTs) assessing the effect of iron isomaltoside ferumoxytol versus iron sucrose on iron deficiency anemia. Meta-analysis was performed using the random-effect model. Results: Four RCTs involving 3892 patients were included in the meta-analysis. Overall, compared with iron sucrose for iron deficiency anemia, iron isomaltoside showed similar change of Hb (SMD=0.14; 95% CI=-0.07 to 0.35; P=0.18), Hb responder (SMD=1.41; 95% CI=0.71 to 2.81; P=0.33), serum ferritin (SMD=15.13; 95% CI=-23.45 to 53.71; P=0.44), and transferrin saturation (SMD=1.20; 95% CI=-1.08 to 3.47; P=0.30). However, iron isomaltoside further improved serum-ferritin at week 2 than iron sucrose (SMD=204.79; 95% CI=38.23 to 371.35; P=0.02). Conclusions: Iron isomaltoside ferumoxytol showed comparable efficacy to iron sucrose for the treatment of iron deficiency anemia. Keywords: Iron isomaltoside ferumoxytol; iron sucrose; iron deficiency anemia; randomized controlled trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

African Health Sciences MEDICINE, GENERAL & INTERNAL-

CiteScore

2.30

自引率

0.00%

发文量

179

审稿时长

>12 weeks

期刊介绍： The African Health Sciences is an internationally refereed journal publishing original articles on research, clinical practice, public health, policy, planning, implementation and evaluation, in the health and related sciences relevant to Africa and the tropics. Its objectives are to: Advocate for and promote the growth of reading culture in sub Saharan Africa; Provide a high quality journal in which health and policy and other researchers and practitioners in the region can and world wide, can publish their work; Promote relevant health system research and publication in the region including alternative means of health care financing, the burden of and solution of health problems in marginalized urban and rural communities amongst the displaced and others affected by conflict; Promote research and the systematic collection and collation and publication of data on diseases and conditions of equity and influence; Promote development of evidence-based policies and guidelines for clinical, public health and other practitioners. African Health Sciences acknowledges support provided by the African Health Journals Partnership Project that is funded by the US National Institutes of Health (through the National Library of Medicine and the Fogarty International Center) and facilitated by the Council of Science Editors.